Pharmacoepidemiological analysis of the treatment of bronchial asthma patients

I. L. Bilichenko, H. V. Demchuk, Y. M. Mostovoy, T. V. Konstantinovich, O. M. Volovik (Vinnitsa, Ukraine)

Source: Annual Congress 2005 - Epidemiology and risk factors in asthma
Session: Epidemiology and risk factors in asthma
Session type: Poster Discussion
Number: 4326
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. L. Bilichenko, H. V. Demchuk, Y. M. Mostovoy, T. V. Konstantinovich, O. M. Volovik (Vinnitsa, Ukraine). Pharmacoepidemiological analysis of the treatment of bronchial asthma patients. Eur Respir J 2005; 26: Suppl. 49, 4326

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Study of the Glutoxim-containing inhalation treatment in bronchial asthma patients
Source: Eur Respir J 2002; 20: Suppl. 38, 373s
Year: 2002

Pharmacoepidemiologic analysis outpatient treatment of bronchial asthma (BA)
Source: Eur Respir J 2005; 26: Suppl. 49, 384s
Year: 2005

Pharmacoepidemiological analysis of the use of bronchodilators in bronchial asthma (BA) treatment in Russia
Source: Eur Respir J 2007; 30: Suppl. 51, 154s
Year: 2007

Efficacy of symbicort administration in patients with bronchial asthma
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009


Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008


Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017

Cost-minimisation analysis of two different inhaled steroids in persistent bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 302s
Year: 2002

Clinical review of long-term pranlukast therapy in adult patients with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Neuroregulatorial therapy of bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 55s
Year: 2002

Pharmacoepidemiologic analysis of medication use for bronchial obstruction therapy
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008


Screening of inhalation technique and treatment adherence of COPD, asthma and ACO patients
Source: International Congress 2019 – Inhalers: adherence and preference
Year: 2019


Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Development of metabolic complicaions in patients with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 130s
Year: 2004

Bronchial thermoplasty for the treatment of asthma patientswith COPD characteristics: an exploratory histopathological evaluation.
Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms
Year: 2020


Gene expression in bronchial biopsies from subjects with persistent asthma and asthma in remission
Source: International Congress 2017 – Asthma genetics and genomics in patients and populations
Year: 2017

A comparative analysis of the non-specific bronchial hyperreactivity in patients with newly discovered bronchial asthma combined with allergic rhinitis
Source: Eur Respir J 2006; 28: Suppl. 50, 235s
Year: 2006

Hair analysis to detect chronic inhaler drug use in asthma or COPD patients
Source: International Congress 2017 – Monitoring novel biomarkers in asthma
Year: 2017



Treating rhinitis in patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001

Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014